1921
Volume 97, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozygous for the glucose-6-phosphate dehydrogenase (G6PD)-deficient variant versus G6PD-normal females, and with reference to primaquine. Six G6PD-heterozygous subjects (G6PD enzyme activity 40–60% of normal) and six G6PD-normal subjects per treatment group received single-dose tafenoquine (100, 200, or 300 mg) or primaquine (15 mg × 14 days). All participants had pretreatment hemoglobin levels ≥ 12.0 g/dL. Tafenoquine dose escalation stopped when hemoglobin decreased by ≥ 2.5 g/dL (or hematocrit decline ≥ 7.5%) versus pretreatment values in ≥ 3/6 subjects. A dose–response was evident in G6PD-heterozygous subjects ( = 15) receiving tafenoquine for the maximum decrease in hemoglobin versus pretreatment values. Hemoglobin declines were similar for tafenoquine 300 mg (−2.65 to −2.95 g/dL [ = 3]) and primaquine (−1.25 to −3.0 g/dL [ = 5]). Two further cohorts of G6PD-heterozygous subjects with G6PD enzyme levels 61–80% ( = 2) and > 80% ( = 5) of the site median normal received tafenoquine 200 mg; hemolysis was less pronounced at higher G6PD enzyme activities. Tafenoquine hemolytic potential was dose dependent, and hemolysis was greater in G6PD-heterozygous females with lower G6PD enzyme activity levels. Single-dose tafenoquine 300 mg did not appear to increase the severity of hemolysis versus primaquine 15 mg × 14 days.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0779
2017-09-07
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/3/tpmd160779.html?itemId=/content/journals/10.4269/ajtmh.16-0779&mimeType=html&fmt=ahah

References

  1. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI, , 2012. The global public health significance of Plasmodium vivax . Adv Parasitol 80: 1111.[Crossref]
  2. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, , 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.[Crossref]
  3. World Health Organization, 2013. World Malaria Report. Geneva, Switzerland: World Health Organization.
  4. Price RN, Nosten F, , 2014. Single-dose radical cure of Plasmodium vivax: a step closer. Lancet 383: 10201021.[Crossref]
  5. Alving AS, Carson PE, Flanagan CL, Ickes CE, , 1956. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124: 484485.
  6. Kamerbeek NM, , et al., 2007. Molecular basis of glutathione reductase deficiency in human blood cells. Blood 109: 35603566.[Crossref]
  7. Chan TK, Chan WC, Weed RI, , 1982. Erythrocyte hemighosts: a hallmark of severe oxidative injury in vivo . Br J Haematol 50: 575582.[Crossref]
  8. Arese P, De Flora A, , 1990. Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency. Semin Hematol 27: 140.
  9. Howes RE, , et al., 2012. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 9: e1001339.[Crossref]
  10. Louicharoen C, , et al., 2009. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science 326: 15461549.[Crossref]
  11. Luzzatto L, Usanga FA, Reddy S, , 1969. Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science 164: 839842.[Crossref]
  12. Shah SS, , et al., 2016. Heterogeneous alleles comprising G6PD deficiency trait in West Africa exert contrasting effects on two major clinical presentations of severe malaria. Malar J 15: 13.[Crossref]
  13. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, Luzzatto L, , 2012. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood 120: 41234133.[Crossref]
  14. Dow GS, , et al., 2011. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J 10: 212.[Crossref]
  15. Walsh DS, , et al., 1999. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 180: 12821287.[Crossref]
  16. Walsh DS, Wilairatana P, Tang DB, Heppner DG, Jr Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S, , 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 39: 10951103.[Crossref]
  17. Llanos-Cuentas A, , et al., 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383: 10491058.[Crossref]
  18. Domingo GJ, , et al., 2013. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J 12: 391.[Crossref]
  19. Huang CS, Hung KL, Huang MJ, Li YC, Liu TH, Tang TK, , 1996. Neonatal jaundice and molecular mutations in glucose-6-phosphate dehydrogenase deficient newborn infants. Am J Hematol 51: 1925.[Crossref]
  20. Vogels IM, Van Noorden CJ, Wolf BH, Saelman DE, Tromp A, Schutgens RB, Weening RS, , 1986. Cytochemical determination of heterozygous glucose-6-phosphate dehydrogenase deficiency in erythrocytes. Br J Haematol 63: 402405.[Crossref]
  21. Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN, , 1977. International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br J Haematol 35: 331340.[Crossref]
  22. Sriprawat K, Kaewpongsri S, Suwanarusk R, Leimanis ML, Lek-Uthai U, Phyo AP, Snounou G, Russell B, Renia L, Nosten F, , 2009. Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood. Malar J 8: 115.[Crossref]
  23. GlaxoSmithKline, Document Number WD2009/01116/00.
  24. Rochford R, Ohrt C, Baresel PC, Campo B, Sampath A, Magill AJ, Tekwani BL, Walker LA, , 2013. Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity. Proc Natl Acad Sci USA 110: 1748617491.[Crossref]
  25. Baird JK, Hoffman SL, , 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 13361345.[Crossref]
  26. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL, , 2012. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology 294: 5460.[Crossref]
  27. Dern RJ, Beutler E, Alving AS, , 1954. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med 44: 171176.
  28. Kheng S, , et al., 2015. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med 13: 203.[Crossref]
  29. Barcellini W, Fattizzo B, , 2015. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers 2015: 635670.[Crossref]
  30. Bolchoz LJ, Budinsky RA, McMillan DC, Jollow DJ, , 2001. Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. J Pharmacol Exp Ther 297: 509515.
  31. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, , 2013. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 81: 133201.[Crossref]
  32. Luzzatto L, Seneca E, , 2014. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol 164: 469480.[Crossref]
  33. Nantakomol D, Paul R, Palasuwan A, Day NP, White NJ, Imwong M, , 2013. Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. Malar J 12: 289.[Crossref]
  34. ClinicalTrials.gov Identifier: NCT01376167, 2011. Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse. Available at: https://clinicaltrials.gov/ct2/show/NCT01376167?term=tafenoquine&rank=14. Accessed December 12, 2016.
  35. LaRue N, , et al., 2014. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg 91: 85461.[Crossref]
  36. Beutler E, , 1984. Red Cell Metabolism: A Manual of Biochemical Methods, 3rd edition. New York, NY: Grune and Strattan.
  37. Van Noorden CJ, Vogels IM, , 1985. A sensitive cytochemical staining method for glucose-6-phosphate dehydrogenase activity in individual erythrocytes. II. Further improvements of the staining procedure and some observations with glucose-6-phosphate dehydrogenase deficiency. Br J Haematol 60: 5763.[Crossref]
  38. Gall JC, Brewer GJ, Dern RJ, , 1965. Studies of glucose-6-phosphate dehydrogenase activity of individual erythrocytes: the methemoglobin-elution test for identification of females heterozygous for G6PD deficiency. Am J Hum Genet 17: 359368.
  39. Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, Wellems TE, Fairhurst RM, , 2012. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Sci Rep 2: 299.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0779
Loading
/content/journals/10.4269/ajtmh.16-0779
Loading

Data & Media loading...

Supplementary Data

Supplemental Figure and Table

  • Received : 02 Oct 2016
  • Accepted : 03 May 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error